Maintaining results of successful induction therapy is an important goal in multiple myeloma.
Here, members of the International Myeloma Working Group review the relevant data …

Transplant-eligible patients with multiple myeloma (MM) now have extended survival after
diagnosis owing to effective modern treatment strategies that include new agents in …

Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant
in elderly patients because the major benefit results from the initial therapy. We report the …

Multiple myeloma management has undergone profound changes in the past thanks to
advances in our understanding of the disease biology and improvements in treatment and …

Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX)
trial of relapsed multiple myeloma patients showed significantly longer time to progression …

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM)
after an initial response. This trial compared the effect of thalidomide maintenance and no …

The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with
newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide …

In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Importance Several trials demonstrated the impact of novel agent-based maintenance in
newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating …

The introduction of thalidomide, bortezomib and lenalidomide has dramatically changed the
treatment paradigm of multiple myeloma (MM). In patients eligible for autologous stem cell …